Moderna expects approval of 2nd RSV shot in 1st half of 2024
Moderna anticipates initial regulatory approvals for its RSV vaccine in first half of 2024.
Source: beckershospitalreview.com
Page 5 - License Application News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from License Application. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In License Application Today - Breaking & Trending Today
Europe Gene Editing Technologies Market Report 2024: Analysis and Forecasts 2023-2032 - Leveraging Collaboration as a Major Key Strategies to Create Opportunities
/PRNewswire/ -- The "Europe Gene Editing Technologies Market: Analysis and Forecast, 2023-2032" report has been added to ResearchAndMarkets.com's offering. The...
Source: prnewswire.com
Outlook Therapeutics® Doses First Subject in NORSE EIGHT
NORSE EIGHT clinical trial is being conducted under Special Protocol Assessment (SPA) from FDA to support expected resubmission of the ONS-5010 Bi...
Source: businessinsider.com
Elon Musk's Starlink Hits Roadblock In India: License Approval Hangs In The Balance Amid Ownership Disclosure Issues
This story was first published on the Benzinga India portal. Elon Musk’s Starlink satellite network, aiming for a 2024 launch in India, might face delays in obtaining its license due to complications similar to those encountered by Verizon Communications (NYSE: VZ) in a previous case. This development could hinder Starlink’s timely entry into the Indian market. What Happened? The primary issue causing the delay is the Indian government’s requirement for complete disclosure of ownership details.
Source: yahoo.com
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-Inferiority Study, NORSE EIGHT, and Announces Private Placement of Up to $172 Million to Advance ONS-5010
Obtained clarity from U.S. Food and Drug Administration on next steps to advance ONS-5010NORSE EIGHT expected to commence in the first quarter of CY2024, enabling potential resubmission of the...
Source: marketscreener.com